Growth factors--BMPs, DBMs, and buffy coat products: are there any proven differences amongst them?
Advances in the understanding of bone repair and improved biotechnology have led to the introduction of new strategies for orthopedic surgeons to control and modulate bone healing using growth factors. However, many orthopedic surgeons are uncertain about the current levels of evidence supporting the use of materials that possess these properties and their therapeutic role in the management of skeletal problems such as fracture, long-bone nonunion, and spine fusion. In particular, the differences amongst osteoinductive factors synthesized by recombinant gene technology, or derived from demineralized bone matrix or platelet rich plasma requires clarification.
Veillette
Christian J H
CJ
Division of Orthopedic Surgery, Department of Surgery, University of Toronto, Canada.
McKee
Michael D
MD
D018488:Bone Demineralization, Pathologic / Q000628:therapy*; D019485:Bone Morphogenetic Proteins / Q000502:physiology* / Q000627:therapeutic use; D001861:Bone Regeneration / Q000502:physiology*; D017102:Fracture Healing / Q000502:physiology; D050723:Fractures, Bone / Q000503:physiopathology*; D006801:Humans; D053657:Platelet-Rich Plasma / Q000502:physiology*; D011475:Prosthesis Failure
D019485:Bone Morphogenetic Proteins